hrp0094p1-89 | Pituitary A | ESPE2021

The Pituitary Tumour Module: Developing a Condition Specific Module within the European Registries for Rare Endocrine Conditions (EuRRECa)

Priego Zurita Ana Luisa , Appelman-Dijkstra Natasha , Biermasz Nienke , Bryce Jillian , Burman Pia , Castano Luis , Dattani Mehul T. , Dekkers Olaf M. , Gan Hoong-Wei , Gaztambide Sonia , Katugampola Harshini , Lasolle Helene , Muller Hermann L. , Raverot Gerald , Rica Itxaso , van Beuzekom Charlotte N. , Vries Friso de , Najafabadi Amir H. Zamanipoor , Ahmed S. Faisal , Pereira Alberto M. ,

Introduction: The European Registries for Rare Endocrine Conditions (EuRRECa) project aims to support the needs of the endocrine and bone community by facilitating the collaboration between patients, health care professionals and researchers across Europe and beyond. It is a project funded by the European Union’s health programme and is the affiliated registry of the European Reference Network for Rare Endocrine Conditions (Endo-ERN). It consists of two r...

hrp0095p1-513 | Growth and Syndromes | ESPE2022

Long-term effectiveness and safety of childhood growth hormone treatment in Turner syndrome from two large observational studies

Backeljauw Philippe , Pietropoli Alberto , Rohrer Tilman

Patients with Turner syndrome (TS) have short stature, despite having normal growth hormone (GH) secretion. Treatment with recombinant human GH is recommended. The effectiveness and safety of Norditropin® (somatropin, Novo Nordisk) over ≤10 years of follow-up were investigated in two non-interventional studies: NordiNet® IOS (NCT00960128) and the ANSWER Program (NCT01009905). Of 2,409 children with TS, 2,377 were included in the full analysis s...

hrp0086p2-p512 | Fat Metabolism and Obesity P2 | ESPE2016

Weight Status in Children at 8 Years: A Prospective Cohort Study

Riano-Galan Isolina , Cristina Rodriguez-Dehli Ana , Olaya-Vazquez Ines , Fernandez-Somoano Ana , Tardon Adonina

Background: Prevalence of childhood obesity represents a major public health concern, given the tracking of body weight from childhood to adult age and its health sequelae.Objective: To describe prevalence of overweight (OW) and obesity (OB) in children at 8 years and investigate the relationship with pre-pregnancy maternal weight and weight status at 4 years.Methods: 485 pregnant mothers recruited between 2004 and 2007 and 409 chi...

hrp0084p3-762 | Diabetes | ESPE2015

Metabolic Control and Glycemic Variability in Pediatric Patients with Type 1 Diabetes in Multiple Daily Injections Therapy Using Automated Bolus Calculator Glucometer

Murillo-Valles Marta , Miguel Federico Vazquez-San , Martinez-Barahona Maria , Bel-Comos Joan

Background: The management of type 1 diabetes is complex, requires a multidisciplinary team and knowledge of the possible advantages of new technologies such as insulin bolus calculators.Aims and objectives: To assess if the use of an automated bolus calculator glucometer Accu-Check Aviva Expert® improves the diabetes control in paediatric patients in multiple daily injections (MDI). To identify which patients benefit most from its use.<p class=...

hrp0097p2-215 | Adrenals and HPA Axis | ESPE2023

Pseudocushing. an exceptional patology in pediatrics

Vela Amaya , Grau Gema , Bermejo Marta , Miguel Vazquez , Garrido Marta , Rica Itxaso

Introduction: PseudoCushing is an unusual pathology. Among adults several cases have been published, however, in paediatrics it is unusual.Objective: Description of a PseudoCushing case from a patient admitted in a hospital and results from a study to discard secondary hypercortisolism due to stress.Patients and methods: 13 years old patient that it is admitted in hospital due to v...

hrp0089p1-p043 | Diabetes &amp; Insulin P1 | ESPE2018

The Effect of Social Burden on Paediatric Diabetes Outcomes

Sales-Luis Madalena , Smith Emma , Ajzensztejn Michal

Introduction: Type 1 diabetes has a major impact on not only the person diagnosed, but also their families/carers. Diabetes control is affected by many factors. Our diabetes patient cohort has a very high level of social burden which we feel impacts significantly on the management of their diabetes.Methods: We performed a retrospective analysis of all young people supported by the Evelina London Children’s Hospital diabetes team in 2017 looking at a...

hrp0086p2-p306 | Diabetes P2 | ESPE2016

Maturity-Onset Diabetes of the Young (MODY): Tracking and Clinical Follow-up

Bezerra Arthur Pires , Ramos Alberto Jose Santos , Braz Adriana Farrant

Background: Maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes, with an autosomal dominant mode of inheritance and high penetrance. To this date, it is known 13 subtypes of MODY with different genetic etiologies. It is characterized by high incidence in the family, an early onset and primary defect in pancreatic β-cell function.Objective and hypotheses: The primary objective of this study is to identify patients with MODY an...

hrp0094p2-280 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status

AL Jorge Alexander , Pietropoli Alberto , Kelepouris Nicky , Horikawa Reiko ,

Objectives: Mutations in PTPN11 are known to be associated with Noonan syndrome (NS), accounting for approximately 50% of cases. Data from a non-interventional and phase 3 study of Norditropin (somatropin; Novo Nordisk A/S, Denmark) were used to assess the impact of PTPN11 mutation status on growth outcomes in children with NS receiving growth hormone therapy (GHT).Methods: The ANSWER (NCT01009905) prog...

hrp0089p2-p080 | Diabetes &amp; Insulin P2 | ESPE2018

Betatrophin as a New Biomarker of Type 1 Diabetes Mellitus in Paediatrics

Ara Laura Bosch i , Villalba Adria , Murillo Marta , Fonolleda Mireia , Vazquez Federico , Rodriguez-Fernandez Silvia , Vives-Pi Marta , Bel Joan

Introduction: Type 1 Diabetes Mellitus (DM1) is an autoimmune disease resulting from the destruction of pancreatic β cells. After the diagnosis, up to 80% of patients spontaneously experience partial remission (PR) for months. New biomarkers are being studied, such as the betatrophin protein (ANGPTL8) of unknown function, but which could be involved in the evolution of DM1, in this phase of RP and even used as a therapeutic target.Methods: Observati...

hrp0097p2-198 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Idiopathic diabetes insipidus: beyond the initial diagnosis

Puerto-Carranza Elsa , Campos Martorell Ariadna , Albaladejo-Moreno Raquel , Laguillo-Sala Gemma , Vazquez Elida , López-Bermejo Abel

Introduction: Diabetes insipidus (DI) is a rare disease in children. In most cases it is acquired and central in origin (CDI). The most frequent cause of acquired CDI is brain tumor and idiopathic forms represent between 20-50% of cases, depending on the series. Autoimmune hypophysitis is a rare cause of DI and is a presumptive diagnosis with a suggestive brain MRI and ACTH and TSH deficiencies as the most common hormonal involvement, although it can manifest ...